Recently, it was reported that BACH2 inhibition reversed β cell failure in type 2 diabetes mice, and treatment with a BACH inhibitor lowered glycemia and increased plasma insulin levels in diabetic mice, and restored insulin secretion in diabetic mice and human islets46, suggesting that BACH inhibition may develop as a promising therapeutic strategy for diabetes. Here, INS is linked to type 2 diabetes mellitus.